Skip to Content

Dyax Strikes Deal for Chinese Sales of Drug

BRIEF: Dyax Strikes Deal for Chinese Sales of Drug [Boston Herald]

From Boston Herald (MA) (February 7, 2013)

Feb. 07--Dyax Corp. of Burlington said today it is partnering with CVie Therapeutics to develop and commercialize its drug Kalbitor in China, Hong Kong and Macau.

Kalbitor is used to treat hereditary angioedema, a rare, genetic condition affecting the immune system that causes swelling of the face and airways and abdominal cramping, and other angioedema indications. The drug is currently marketed in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.

Under terms of the exclusive license agreement, Dyax will receive an undisclosed upfront payment and is eligible to receive future development, regulatory and sales milestone payments. Dyax is also eligible to receive royalties on net product sales.

CVie is a subsidiary of Lee’s Pharmaceutical Holdings Ltd., a research-based biopharmaceutical company listed in Hong Kong. The company will purchase drug product from Dyax on a cost-plus basis for commercial supply.


(c)2013 the Boston Herald

Visit the Boston Herald at

Distributed by MCT Information Services


Posted: February 2013